Skip to main
LUCD
LUCD logo

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics has demonstrated solid operational growth, with EsoGuard test volume increasing by 2% year-over-year in Q3 2025, suggesting a steady demand for its diagnostic services. The company's efforts to broaden coverage through private payers, employer-based plans, and its marketing initiatives, such as the #CheckYourFoodTube events, position it for expedited revenue growth, especially with anticipated enhancements to Medicare coverage. Furthermore, a successful MolDX CAC meeting has catalyzed increased engagement with Medicare, potentially unlocking significant revenue streams, which underscores the favorable valuation outlook for Lucid Diagnostics.

Bears say

Lucid Diagnostics Inc. reported disappointing revenue results in 3Q25, falling short of consensus estimates, which raises concerns about the company's ability to gain traction in a competitive market. Additionally, the decline in processed EsoGuard tests, dropping from previous quarters, signals potential challenges in the adoption and effectiveness of its product marketing strategies. The financial outlook is further complicated by significant risks related to liquidity, regulatory approvals, and reimbursement issues, which could hinder the company's growth and operational stability.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.